BG Medicine Revenues Jump to $622K in Q2; Firm Withdraws CardioScore 510(k)
August 10, 2012
BG Medicine Revenues Jump to $622K in Q2; Firm Withdraws CardioScore 510(k)
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- BG Reports 257 Percent Jump in Q3 Revenues, May Offer CardioScore Through CLIA Lab as LDT
November 16, 2012 / ProteoMonitor - BG Medicine Posts 85 Percent Jump in Q1 Revenues, Appoints New CEO
May 10, 2013 / ProteoMonitor - With $10M in Funding and New Distribution Pact, Aviir Rolls out Protein Test for Cardiac Risk
March 1, 2013 / ProteoMonitor - CMS Declines to Offer Higher Payment Rate for BG Medicine's Galetin-3 Test Under New CPT Code
November 9, 2012 / ProteoMonitor - BG Medicine Files 510(k) for Automated Galectin-3 Test on Abbot Architect Platform
July 27, 2012 / ProteoMonitor